These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 36889774)
1. Retrospective Analysis of the Expression of CD56 in Multiple Myeloma with Bone-Related Extramedullary Diseases. Chen Q; Zheng X; Lin Q; Chen J Ann Clin Lab Sci; 2023 Jan; 53(1):14-20. PubMed ID: 36889774 [TBL] [Abstract][Full Text] [Related]
2. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases. Deng S; Xu Y; An G; Sui W; Zou D; Zhao Y; Qi J; Li F; Hao M; Qiu L Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):286-91. PubMed ID: 25640025 [TBL] [Abstract][Full Text] [Related]
3. Cytogenetic and survival analysis in 315 multiple myeloma patients; five with orbital and eight with extramedullary disease. Tucker SM; Zaihra T Orbit; 2023 Dec; 42(6):603-611. PubMed ID: 36697375 [TBL] [Abstract][Full Text] [Related]
4. Bone-Related Extramedullary Disease in Newly Diagnosed Myeloma Patients is an Independent Poor Prognostic Predictor. Wang Y; Liu A; Xu T; Yin J; Chen W Clin Med Insights Oncol; 2022; 16():11795549221109500. PubMed ID: 35875418 [TBL] [Abstract][Full Text] [Related]
5. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Weinstock M; Aljawai Y; Morgan EA; Laubach J; Gannon M; Roccaro AM; Varga C; Mitsiades CS; Paba-Prada C; Schlossman R; Munshi N; Anderson KC; Richardson PP; Weller E; Ghobrial IM Br J Haematol; 2015 Jun; 169(6):851-8. PubMed ID: 25833301 [TBL] [Abstract][Full Text] [Related]
6. Identification of long noncoding RNA Chen T; Sun Z; Cui Y; Ji J; Li Y; Qu X Hematology; 2023 Dec; 28(1):2164449. PubMed ID: 36657019 [TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and survival outcomes of newly diagnosed multiple myeloma patients presenting with extramedullary disease: A retrospective study. Gao S; Li Q; Dong F; Yang P; Chen Y; Wang J; Wang Y; Jing H Leuk Res; 2022 Apr; 115():106793. PubMed ID: 35248783 [TBL] [Abstract][Full Text] [Related]
8. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Varga C; Xie W; Laubach J; Ghobrial IM; O'Donnell EK; Weinstock M; Paba-Prada C; Warren D; Maglio ME; Schlossman R; Munshi NC; Raje N; Weller E; Anderson KC; Mitsiades CS; Richardson PG Br J Haematol; 2015 Jun; 169(6):843-50. PubMed ID: 26032514 [TBL] [Abstract][Full Text] [Related]
9. Identification of patients at high risk of secondary extramedullary multiple myeloma development. Stork M; Sevcikova S; Minarik J; Krhovska P; Radocha J; Pospisilova L; Brozova L; Jarkovsky J; Spicka I; Straub J; Pavlicek P; Jungova A; Jelinek T; Sandecka V; Maisnar V; Hajek R; Pour L Br J Haematol; 2022 Feb; 196(4):954-962. PubMed ID: 34726261 [TBL] [Abstract][Full Text] [Related]
10. Interleukin-17 receptor expression on vascular endothelial cells of masses of skeletal extramedullary disease in myeloma patients. Yang JZ; Li Y; Sun LX; Fang J; Kong LJ; Zhang JQ Pathol Res Pract; 2014 Sep; 210(9):586-90. PubMed ID: 24916639 [TBL] [Abstract][Full Text] [Related]
11. Pomalidomide-based therapy for extramedullary multiple myeloma. Li Y; Ji J; Lu H; Li J; Qu X Hematology; 2022 Dec; 27(1):88-94. PubMed ID: 35068387 [TBL] [Abstract][Full Text] [Related]
12. Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns. Danhof S; Rasche L; Mottok A; Steinmüller T; Zhou X; Schreder M; Kilian T; Strifler S; Rosenwald A; Hudecek M; Einsele H; Gerhard-Hartmann E Ann Hematol; 2021 Jun; 100(6):1537-1546. PubMed ID: 33575947 [TBL] [Abstract][Full Text] [Related]
13. [Clinical Analysis of 46 Cases of Multiple Myeloma with Extramedullary Disease]. Chao Y; Fan L; Gao XY; Ma YP Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):115-121. PubMed ID: 33554807 [TBL] [Abstract][Full Text] [Related]
14. Negative E-cadherin expression on bone marrow myeloma cell membranes is associated with extramedullary disease. Hirao M; Yamazaki K; Watanabe K; Mukai K; Hirose S; Osada M; Tsukada Y; Kunieda H; Denda R; Kikuchi T; Sugimori H; Okamoto S; Hattori Y F1000Res; 2022; 11():245. PubMed ID: 35646332 [No Abstract] [Full Text] [Related]
15. Extramedullary multiple myeloma. Weinstock M; Ghobrial IM Leuk Lymphoma; 2013 Jun; 54(6):1135-41. PubMed ID: 23210572 [TBL] [Abstract][Full Text] [Related]
16. Genetic Abnormalities in Extramedullary Multiple Myeloma. McAvera R; Quinn J; Murphy P; Glavey S Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511018 [TBL] [Abstract][Full Text] [Related]
18. [Research Progress on Multiple Myeloma with Extramedullary Disease]. Wang L; Zhang YZ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):945-8. PubMed ID: 27342539 [TBL] [Abstract][Full Text] [Related]
19. High nuclear expression of Twist1 in the skeletal extramedullary disease of myeloma patients predicts inferior survival. Yang JZ; Lian WG; Sun LX; Qi DW; Ding Y; Zhang XH Pathol Res Pract; 2016 Mar; 212(3):210-6. PubMed ID: 26774288 [TBL] [Abstract][Full Text] [Related]
20. The Assessment of CD56 and CD117 Expressions at the Time of the Diagnosis in Multiple Myeloma Patients. Ceran F; Falay M; Dağdaş S; Özet G Turk J Haematol; 2017 Aug; 34(3):226-232. PubMed ID: 28270374 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]